Health
Cancer Prevention
Female CEOs
Iovance Biotherapeutics
$15.629876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$15.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.58 (3.86%) Today
+$0.01 (0.06%) After Hours
Why Robinhood?
You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!
About
Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
CEO
Employees
88
Headquarters
San Carlos, California
Founded
2007
Market Cap
1.85B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.32M
High Today
$16.52
Low Today
$15.15
Open Price
$15.30
Volume
1.83M
52 Week High
$18.25
52 Week Low
$7.26
Collections
Health
Cancer Prevention
Female CEOs
Biotechnology
Medical
Therapy
Technology
2013 IPO
News
Seeking AlphaMay 18
Iovance Biotherapeutics: Updating The Investment Thesis
We revisit this promising developmental firm and its evolving investment case in the paragraphs below. We highlight recent trial data and what analysts are saying on the company. "Long books, when read, are usually overpraised, because the reader wishes to convince others and himself that he has not wasted his time.” ― E.M. Forster, Aspects of the Novel Iovance Biotherapeutics (IOVA) is one of several small biotech holdings making big moves this week for the Busted IPO Forum model portfolio. The company ...
BenzingaMay 16
Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward
Shares of small-cap biotech Iovance Biotherapeutics Inc (NASDAQ: IOVA) were making a strong upward move Thursday on more than 10 times their average volume.
The Motley FoolMay 8
Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2019 Earnings Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Iovance Biotherapeutics first-quarter 2019 financial results conference call. [Operator instructions] Please be advised that the call is being recorded at the company's request. Now I would like to turn the conference over to Tim Morris, chief financial officer at Iovance. Sir, please go ahea...
Price Paid on Robinhood
20% Higher
Right Now
52 Week Low
$7.26
Average Price Paid
$13.02
52 Week High
$18.25
Earnings
-$0.36
-$0.33
-$0.30
-$0.27
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.29 per share
Actual
-$0.30 per share